Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience

[1]  M. Irazabal,et al.  Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Renal Disease. , 2020, Journal of the American Society of Nephrology.

[2]  J. Mejía-Vilet,et al.  Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage , 2020, Clinical Rheumatology.

[3]  H. Denley,et al.  ANCA renal risk score predicts outcome in the Manchester cohort. , 2019, Kidney international.

[4]  U. Specks,et al.  291. EFFICACY OF RITUXIMAB AND PLASMA EXCHANGE IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS WITH SEVERE RENAL DISEASE , 2019, Rheumatology.

[5]  U. Panzer,et al.  Development and validation of a renal risk score in ANCA-associated glomerulonephritis. , 2018, Kidney international.

[6]  N. Chen,et al.  Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis , 2017, The Journal of Rheumatology.

[7]  J. Levy,et al.  Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  S. Quaglini,et al.  Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. , 2015, Clinical and experimental rheumatology.

[9]  L. Punzi,et al.  Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. , 2015, Clinical and experimental rheumatology.

[10]  H. Doll,et al.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. , 2015, Annals of the rheumatic diseases.

[11]  P. Nightingale,et al.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis , 2009, Annals of the rheumatic diseases.